Amgen's trebananib down, not out in ovarian cancer

Trebananib did not significantly improve overall survival for women with recurrent ovarian cancer, a secondary endpoint of the TRINOVA-1 trial, but Amgen has two more Phase III opportunities to show a meaningful improvement for patients with the difficult cancer.